Fate Therapeutics FATE
NASDAQ FATE
$2.48 +0.06 (+2.48%)
As of: Sep 4, 2026 · 3:59 PM EDT

Fate Therapeutics (FATE) Operating Margin Growth (1y) (2013 - 2026)

Analysis

Fate Therapeutics (FATE) Operating Margin Growth (1y) (2013 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -143.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 78.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1,135.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 7,666.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1,238.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 2,002.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -1,651.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 29,091.00
10 Fate Therapeutics 299.79 Mn 299.79 Mn - 44,315.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 44,315.00
Mar 31, 2026 -635.00
Dec 31, 2025 78,355.00
Sep 30, 2025 -29,125.00
Jun 30, 2025 -127,282.00
Mar 31, 2025 11,881.00
Dec 31, 2024 -45,135.00
Sep 30, 2024 93,394.00
Jun 30, 2024 604,006.00
Mar 31, 2024 -260,441.00
Dec 31, 2023 -272,320.00
Sep 30, 2023 -206,114.00
Jun 30, 2023 -625,774.00
Mar 31, 2023 35,593.00
Dec 31, 2022 26,125.00
Sep 30, 2022 -19,268.00
Jun 30, 2022 -9,927.00
Mar 31, 2022 1,033.00
Dec 31, 2021 -19,637.00
Sep 30, 2021 3,261.00